Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.
Vounatsos out as Biogen appears to concede defeat over Aduhelm
Alzheimer's Disease, Alzheimer's Diseases, Alzheimer’s, Alzheimer’s disease, Business, Centers for Medicare & Medicaid Services, Centers for Medicare and Medicaid Services (CMS), Cerebral edema, Dementia, Departures, Edema, Medicare and Medicaid Services, Medicare and Medicaid Services (CMS), Medicare Part D, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuroscience, People on the MoveBruised and battered by its failings with the controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer.
Cassava Sciences hits back at NYT for alleged “pre-set narrative”
Alzheimer's Diseases, Alzheimer’s, Alzheimer’s Disease, Alzheimer’s disease, Alzheimer’s disease, Brain Diseases, Centers for Medicare & Medicaid Services, CNS Disorders, Dementia, Early Alzheimer's Disease, Early Alzheimer’s, Financing, Neurodegenerative Disorders, Neuroscience, New York Times, Newspapers, Papers, R&D, R&D, Research Papers, Scientific Papers, Series ACassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
Biogen filed a lawsuit against a New York life sciences company over alleged patent infringements related to the experimental Alzheimer’s disease treatment aducanumab.
Powered by Xconomy, November 2019’s What’s Next in Neuroscience Therapies event brought together scientists, entrepreneurs and biotech executives at the Hyatt Regency San Francisco to discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, dementia and Alzheimer’s disease.
Roche is testing the company’s “brain shuttle” in humans, with the Swiss drugmaker hoping to rejuvenate the theory that removing amyloid plaques from the brains of patients with Alzheimer’s disease will prove effective despite repeated failures.
Allergan will pay $750 million to settle a class action lawsuit from a group of direct purchasers of the Alzheimer’s disease therapy Namenda in a resolution to the litigation that was set to face trial.
Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations
Alzheimer's Diseases, Biosimilars, Business, Fibromyalgia, J.P. Morgan Healthcare Conference, Layoffs, M&A, Neuroscience, Pain, Parkinson's Disease, Partnerships, R&D, Reorganization, Start-Ups, Succession Plans, Venture Capital, White Blood CellsPfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
7 Biotech Trends to Look Out for in 2019
Alzheimer's Diseases, Analysts, Business, Cancer, CAR-T Therapy, Clinical Trials, CRISPR/Cas9, Department of Health and Human Services (HHS), Drug Pricing, FDA, Immuno-oncology, Initial Public Offering (IPO), National Institutes of Health, Opioids, Politics, R&D, Spinal Muscular Atrophy (SMA), Therapeutics, TrendsHere are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
CDC: 14 Million Americans Will Have Alzheimer’s by 2060
African-Americans, Alzheimer's Diseases, American Indians, Analysts, Biopharma, Clinical Trials, Dementia, Ethnicity, Hispanics, Investors, Medical Journals, Population, R&D, Race, U.S. Census Bureau, U.S. Centers for Disease Control and PreventionIncidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.